Table 4. Skeletal phenotype of adult Bmp2^Flox/Flox; Prx1-Cre mice after intermittent PTH therapy.

Ten week-old mice were given intermittent PTH_1-34 therapy (100 mg/kg, subcutaneous) for 14 days. Bone mass was analyzed in the femur by microcomputed tomography (microCT). Trabecular bone at the distal metaphysis and cortical bone at the mid-diaphysis of the femur are presented as group mean ±s.d. and statistically compared by 2-way ANOVA. BV/TV, bone volume fraction; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, Trabecular separation; Tt.Ar, total cross-sectional area; Ct.Ar, cortical bone area; Ct.Ar/Tt.Ar, cortical area fraction; Ct.Th, average cortical thickness; Ct.Po, cortical porosity; Ma.V, marrow volume; Imin, minimum moment of inertia. P^a ≤ 0.05 vs. WT. P^b ≤ 0.05 vs. Vehicle.

MicroCT Femur, 10 wk	Bmp2Flox/Flox		Bmp2Flox/Flox; Prx1-Cre
Treatment	Vehicle	PTH	Vehicle	PTH
N	5	5	5	5
BV/TV (%)	12.3 ± 3	16.7 ± 2b	15.0 ± 3.0	21.0 ± 1.4b
Tb.N (1/mm)	4.90 ± 0.5	5.50 ± 0.9	6.10 ± 0.7a	5.70 ± 0.6
Tb.Th (mm)	0.04 ± 0.003	0.04 ± 0.005	0.04 ± 0.001	0.05 ± 0.003b
Tb.Sp (mm)	0.20 ± 0.02	0.19 ± 0.05	0.16 ± 0.02	0.16 ± 0.02
Tt.Ar (mm2)	1.60 ± 0.01	1.90 ± 0.3	0.80 ± 0.08a	0.90 ± 0.18
Ct.Ar (mm2)	0.76 ± 0.07	0.88 ± 0.07b	0.58 ± 0.06a	0.72 ± 0.1b
Ct.Ar/Tt.Ar (%)	0.47 ± 0.04	0.46 ± 0.03	0.75 ± 0.01	0.80 ± 0.027
Ct.Th (mm)	0.19 ± 0.02	0.19 ± 0.005	0.25 ± 0.01a	0.30 ± 0.014b
Ct. Po (%)	3.58 ± 0.28	4.06 ± 0.1b	3.38 ± 0.3	2.80 ± 0.18b
Ma.V (mm3)	1.03 ± 0.16	1.21 ± 0.27	0.23 ± 0.03a	0.21 ± 0.07b
Imin (mm4)	0.11 ± 0.01	0.15 ± 0.03b	0.03 ± 0.01a	0.04 ± 0.02